This document provides information about an upcoming webinar on drug types including biosimilars and generics. It outlines details like the speaker, how to ask questions during the webinar, and instructions for accessing the webinar archive and following along on Twitter. It also provides brief bios of the speaker and gives technical instructions for participating in the webinar platform. Finally, it lists some resources and includes a standard disclaimer.
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...Swapnil Fernandes
- European pharmaceutical legislation provides a comprehensive framework for the marketing authorisation of vaccines.
- In contrast to the European scenario, the Indian scenario for vaccines is relatively less regulated and follows the same process of approval as other biologics in spite of having a National Handbook for Vaccine Policy.
- Vaccine authorisation in the US, as is the case in EU, is a more straightforward process than in most other markets as the USFDA has provided vaccines with a distinct set of regulations in concerned areas of safety and quality.
Bioavailability and Bioequivalence StudiesPranav Sopory
BA and BE studies.
Seminar presented in All India Institute of Medical Sciences (AIIMS - New Delhi).
Focus in Pharmacokinetic parameters (Cmax, AUC)
Single dose PK study, Steady state PK study, Modified drug release PK study, In vivo mechanisms, invitro mechanisms, Pharmacodynamic Study, Comparatice Clinical Trials. Biowavers and Biosimilimars.
Reference: CDSCO guideline, USFDA guideline, ICH guidelines
Definition of biopharmaceuticals and biosimilars, Steps involved in manufacturing biopharmaceuticals, Points of differences between Biosimilars and Chemical Generics, Related issues with biosimilars
This slide show reflects general considerations of Bio-availability & Bio-equivalence studies for orally administered drugs. The presentation also accommodates US - FDA's approach and specific recommendations for such studies.
Biologics (eg, vaccines, blood and blood components, somatic cells, gene therapy, tissues, therapeutic proteins) are regulated by the US Food and Drug Administration (FDA). Biologics/Biosimilars/Biobetters are widely used to diagnose, prevent, treat, and cure diseases and medical conditions.
Naveen Kumar Singh received his B.Sc. in Biotechnology (2007) at University of Pune (Pune, India), M.Sc. in Biotechnology (2009) at Jaipur National University (Jaipur, India), and Ph.D. in Biochemical Engineering (2016) at Jacobs University Bremen (Bremen, Germany).
During his Ph.D., Naveen worked under the supervision of Prof. Marcelo Fernández-Lahore. His research dealt with designing experiments for developing fiber-based and cryogel-based adsorbents for capturing large therapeutic biomolecules (proteins, plasmids, and monoclonal antibodies). He had successfully evaluated the in-house fiber- and cryogel-based chromatographic adsorbents with the commercially available adsorbents and the in-house adsorbents had shown similar or higher productivities compared to the commercial adsorbents.
In February 2017, Naveen joined the group of Prof. Merlin L. Bruening in the Department of Chemical and Biomolecular Engineering at the University of Notre Dame as a Postdoctoral Research Associate. His current research focuses on developing novel bioseparation processes by introducing polyelectrolyte multilayer films onto membranes/monoliths for the purification of biotherapeutics like monoclonal antibodies.
Publications:
N. K. Singh, et al, “Preparation and Characterization of Grafted Cellulosic Fibers and their Applications in Protein Purification“, Sep. Purif. Technol., 143 (2015) pp. 177–183. https://www.sciencedirect.com/science/article/pii/S1383586615000714
N. K. Singh, et al, “Direct Capture of His6-tagged Proteins Using Megaporous Cryogels Developed for Metal-ion Affinity Chromatography“, inAffinity Chromatography (Ed.: S. Reichelt), Spinger, New York, USA, Methods in Molecular Biology, 1286 (2015) pp. 201–212. http://link.springer.com/protocol/10.1007/978-1-4939-2447-9_16
N. K. Singh, et al, “Gamma ray mediated functionalization of monolithic cryogels for macro-biomolecule purification“, N. Biotechnol., 31, Supplement (2014) pp. S127. http://www.sciencedirect.com/science/article/pii/S1871678414019906
N. K. Singh, et al, “High capacity cryogel-type adsorbents for protein purification“, J. Chromatogr. A, 1355 (2014) pp. 143–148. https://www.sciencedirect.com/science/article/pii/S0021967314008899
N. S. Bibi, N. K. Singh, et al, “Synthesis and performance of megaporous immobilized metal-ion affinity cryogels for recombinant protein capture and purification“, J. Chromatogr. A, 1272 (2013) pp. 145–149. https://www.sciencedirect.com/science/article/pii/S0021967312017670
Blog articles:
What are cryogels? https://www.biochemadda.com/cryogels-monolith-ion-exchange-affinity-chromatography/
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...Swapnil Fernandes
- European pharmaceutical legislation provides a comprehensive framework for the marketing authorisation of vaccines.
- In contrast to the European scenario, the Indian scenario for vaccines is relatively less regulated and follows the same process of approval as other biologics in spite of having a National Handbook for Vaccine Policy.
- Vaccine authorisation in the US, as is the case in EU, is a more straightforward process than in most other markets as the USFDA has provided vaccines with a distinct set of regulations in concerned areas of safety and quality.
Bioavailability and Bioequivalence StudiesPranav Sopory
BA and BE studies.
Seminar presented in All India Institute of Medical Sciences (AIIMS - New Delhi).
Focus in Pharmacokinetic parameters (Cmax, AUC)
Single dose PK study, Steady state PK study, Modified drug release PK study, In vivo mechanisms, invitro mechanisms, Pharmacodynamic Study, Comparatice Clinical Trials. Biowavers and Biosimilimars.
Reference: CDSCO guideline, USFDA guideline, ICH guidelines
Definition of biopharmaceuticals and biosimilars, Steps involved in manufacturing biopharmaceuticals, Points of differences between Biosimilars and Chemical Generics, Related issues with biosimilars
This slide show reflects general considerations of Bio-availability & Bio-equivalence studies for orally administered drugs. The presentation also accommodates US - FDA's approach and specific recommendations for such studies.
Biologics (eg, vaccines, blood and blood components, somatic cells, gene therapy, tissues, therapeutic proteins) are regulated by the US Food and Drug Administration (FDA). Biologics/Biosimilars/Biobetters are widely used to diagnose, prevent, treat, and cure diseases and medical conditions.
Naveen Kumar Singh received his B.Sc. in Biotechnology (2007) at University of Pune (Pune, India), M.Sc. in Biotechnology (2009) at Jaipur National University (Jaipur, India), and Ph.D. in Biochemical Engineering (2016) at Jacobs University Bremen (Bremen, Germany).
During his Ph.D., Naveen worked under the supervision of Prof. Marcelo Fernández-Lahore. His research dealt with designing experiments for developing fiber-based and cryogel-based adsorbents for capturing large therapeutic biomolecules (proteins, plasmids, and monoclonal antibodies). He had successfully evaluated the in-house fiber- and cryogel-based chromatographic adsorbents with the commercially available adsorbents and the in-house adsorbents had shown similar or higher productivities compared to the commercial adsorbents.
In February 2017, Naveen joined the group of Prof. Merlin L. Bruening in the Department of Chemical and Biomolecular Engineering at the University of Notre Dame as a Postdoctoral Research Associate. His current research focuses on developing novel bioseparation processes by introducing polyelectrolyte multilayer films onto membranes/monoliths for the purification of biotherapeutics like monoclonal antibodies.
Publications:
N. K. Singh, et al, “Preparation and Characterization of Grafted Cellulosic Fibers and their Applications in Protein Purification“, Sep. Purif. Technol., 143 (2015) pp. 177–183. https://www.sciencedirect.com/science/article/pii/S1383586615000714
N. K. Singh, et al, “Direct Capture of His6-tagged Proteins Using Megaporous Cryogels Developed for Metal-ion Affinity Chromatography“, inAffinity Chromatography (Ed.: S. Reichelt), Spinger, New York, USA, Methods in Molecular Biology, 1286 (2015) pp. 201–212. http://link.springer.com/protocol/10.1007/978-1-4939-2447-9_16
N. K. Singh, et al, “Gamma ray mediated functionalization of monolithic cryogels for macro-biomolecule purification“, N. Biotechnol., 31, Supplement (2014) pp. S127. http://www.sciencedirect.com/science/article/pii/S1871678414019906
N. K. Singh, et al, “High capacity cryogel-type adsorbents for protein purification“, J. Chromatogr. A, 1355 (2014) pp. 143–148. https://www.sciencedirect.com/science/article/pii/S0021967314008899
N. S. Bibi, N. K. Singh, et al, “Synthesis and performance of megaporous immobilized metal-ion affinity cryogels for recombinant protein capture and purification“, J. Chromatogr. A, 1272 (2013) pp. 145–149. https://www.sciencedirect.com/science/article/pii/S0021967312017670
Blog articles:
What are cryogels? https://www.biochemadda.com/cryogels-monolith-ion-exchange-affinity-chromatography/
Hope S. Rugo, MD, FASCO, prepared useful Practice Aids pertaining to biosimilars for this CME/MOC/CNE/CPE activity titled "Biosimilars as Partners in Oncology: Expert Guidance on Understanding and Incorporating Biosimilar Agents in Real-World Care." For the full presentation, monograph, complete CME/MOC/CNE/CPE information, and to apply for credit, please visit us at http://bit.ly/38DBgFb. CME/MOC/CNE/CPE credit will be available until April 27, 2021.
Biosimilars, a pharmacist’s perspectiveBiosimilars
Not many things can profoundly affect and perhaps even alter a profession, let alone the pharmacist’s profession. However, biosimilars might do just that.
Biosimilars are biological generics drugs.They undergo a rigorous evaluation to get approved.How to prove biosimilariy from analytical comparability is explained using a recently approved US FDA bio-similar monoclonal antibody.
An introductory presentation (ppt) on biosimilars and guidelines related to their approval along with the challenges faced by biosimilar industries in India.
The present slide focuses on the applications and different uses of biosimilars along with the basic difference in between biosimilars and bioequivalence.
By 2020, it is predicted that the Biosimilar market globally will cross US$20 Billion. With an increasing number of patent expires and more clear regulation processes, Biosimilars have emerged as one of the fastest-growing categories in the bio-pharmaceutical sector. The increasing need for cost-effective treatment is one of the major factors driving this market’s growth in the coming years. Biosimilars cost 10% to 30% lesser than their parent products which is one of the primary factors fueling their adoption.
Dr. Murphy presents slides discussing general screening trends in the US, including how the US compares to other countries, different screening modalities, and differences in screening by:
-Age
-Gender
-Geography
-Race/Ethnicity
Looking to kick start your physical activity? Hoping to learn about how body movement can be a huge benefit for CRC patients and survivors? Curious about Climb for a Cure? Join this interactive webinar featuring Karia Coleman, MSK, personal trainer and athletic strength coach, and Fight CRC advocates as they discuss the importance, challenges, and joys of physical activity.
From bowel frequency, pain, and more, many colorectal cancer treatments lead to digestive side effects. Join this webinar with Dr. Cathy Eng to learn all about the digestive system, the side effects that are common due to CRC treatment, and how to manage those side effects.
Maine recently passed major colorectal cancer (CRC) policy at the state level. Join us to listen to their story and learn what worked well for CRC state advocacy!
Indiana just passed major colorectal cancer (CRC) policy this year. Join us to listen to their story and learn what worked well for CRC advocacy in Indiana!
Kentucky was one of the first states in the US to pass major colorectal cancer (CRC) policy. Join us to listen to their story and learn what worked well for CRC state advocacy!
Join Fight CRC in a webinar about biomarkers. In this session, Dr. Chris Lieu will focus the discussion on the NTRK biomarker, in addition to ctDNA, and Next-Generation Sequencing.
Join us as Eden Stotsky-Himelfarb, BSN, RN from Johns Hopkins Medicine discusses how to manage after a colorectal cancer diagnosis. In this session, she will cover understanding diagnoses, shared decision making, managing mental health, talking to family and colleagues, and more.
Some colorectal cancer treatments lead to side effects of the skin. In this webinar, Dr. Nicole LeBoeuf will discuss these specific side effects. She will talk about why they occur, how to prepare for them, and how to manage them.
Hear about the latest breaking colorectal cancer research! Fight CRC will be joined by Dr. Axel Grothey who will spend the hour detailing the research presented at the 2020 Gastrointestinal (GI) Cancers Symposium hosted by the American Society of Clinical Oncology.
Anticipating the end of life and making decisions about medical care at this time can be difficult and distressing for people with cancer and their loved ones. However, it is incredibly important to plan for the transition to end-of-life care.
In this webinar, we will discuss questions to ask when considering an end to curative treatment, what to expect with hospice and end-of-life care, a new medical care team, advance directives and healthcare proxies, options for pain, the role of caregivers and loved ones, and more.
In this webinar, Dr. Angela Nicholas, Dr. Chris Heery, and Wenora Johnson discuss all things clinical trials. Dr. Nicholas, a family practitioner and caregiver to her late husband, John MacCleod will dive into her experience searching for clinical trials along with advice to those currently searching, or planning on searching in the future. Dr. Heery, Chief Medical Officer for Precision Biosciences will spend time dispelling myths around clinical trials and challenges to enrollment, and Wenora Johnson, a stage III colon cancer survivor will describe the process and her point of view curating trials in the Fight CRC trial finder.
In this webinar, Dr. Popp will discuss everything you need to know about palliative care! This is an important webinar for colorectal cancer patients and their loved ones.
eeling worn out and exhausted all the time? You may be experiencing cancer-related fatigue. Tune in to this webinar to learn what cancer-related fatigue is, how to spot it, and how to manage it.
In this webinar, Dr. Azad discusses colorectal cancer recurrence. She addresses things to do to help reduce the risk of recurrence, in addition to what steps should be taken if colon or rectal cancer returns.
Join Fight CRC and Dr. Scott Kopetz to learn about the latest breaking colorectal cancer research from the American Society of Clinical Oncology 2019 Annual Conference.
May 2019 – What You Need to Know About Chemotherapy Induced Neuropathy WebinarFight Colorectal Cancer
Neuropathy is a common side effect for colorectal cancer patients. It is a side effect that can be incredibly challenging to manage, and can affect daily living. Join this informative webinar to learn all about neuropathy—why it happens, how to prepare for it, and methods to try and reduce its effects. This is an important webinar for all survivors and patients! Dana will speak from both the medical professional and patient angle, as she is a colon cancer survivor herself!
A cancer diagnosis and cancer treatment can be traumatic. An experience with cancer can lead to serious psychological distress that should be addressed. In this webinar, Schuyler Cunningham, Clinical Social Worker, talks about what trauma is, how to identify it, and what steps to take next.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
2. TODAY’S WEBINAR
SPEAKER(S)
Stevan Lalich, Pharm.D.
QUESTIONS
Ask a question in the panel on the RIGHT SIDE of your
screen
WEBINAR ARCHIVE
FightCRC.org/webinar
TWEET ALONG
Follow along via Twitter – use the hashtag #CRCWebinar
POST WEBINAR
Expect an email with links to the material & a survey. If
you fill it out, we’ll send you a Fight CRC bracelet.
3. We are using LogMeIn GoToWebinar platform
The side control panel can be adjusted using the
orange arrow
Questions are asked by opening the “Questions”
tab – the arrow opens the box
Not all questions are addressed during the
presentation depending on time and quantity, but if
necessary will be followed up individually
If you are new to GoToWebinar and experience
streaming problems, shut down other high
bandwidth services such as Facebook, IM, or
hangout systems during presentation
The “Audio” tab allows you to select either your
computer or phone to listen in
WEBINAR TECH
5. FIGHTCOLORECTALCANCER
DISCLAIMER
The information and services
provided by Fight Colorectal Cancer
are for general informational
purposes only. The information and
services are not intended to be
substitutes for professional medical
advice, diagnoses or treatment.
If you are ill, or suspect that you are
ill, see a doctor immediately. In an
emergency, call 911 or go to the
nearest emergency room.
Fight Colorectal Cancer never
recommends or endorses any
specific physicians, products or
treatments for any condition.
6. StevanLalich
Pharm.D. Stevan Lalich has served in several clinical roles during his
current 5-year tenure at CVS Health. In his current role, he
focuses on developing and executing payer strategies
specifically for the oncology therapy class. Prior to this
current position Stevan served as the Oncology Clinical
Therapy Manager on the Specialty Manufacturer Services
Team, where his scope of responsibility focused on clinical
oversight of the oncology drug therapy portfolio for the
specialty business unit.
He also served as the oncology subject matter expert for
the CVS Specialty Trade team for consultant RFP
responses and manufacturer capabilities presentations in
efforts to secure access to oncology pipeline assets.
Stevan regularly provides oncology-related clinical therapy
training across the organization to various audiences as
needed including specialty pharmacy operations
personnel and oncology prescriber team members.
Stevan obtained his Pharm.D. degree from the University
of Illinois.
8. • Avastin
• Epogen
• Herceptin
• Humira
• Neulasta
• Remicade
• Rituxan
What Are Biologic Medicines?
• Large, complex molecules
• Typically derived from living cells
• microorganism, plant cell, or animal cell
• Used in the treatment, diagnosis or
prevention of disease
• Highly sensitive to manufacturing
and handling conditions
• Almost always injectable
• Can be specialty or non-specialty
1. “Biosimilar Competition in the United States: Statutory Incentives, Payers and Pharmacy Benefit Managers,” Health Affairs, February 2015.
This slide contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty.
Spending on U.S. biologics is expected to increase annually
by more than 10 percent until key biosimilars are launched.1
EXAMPLES OF SPECIALTY
BIOLOGICS
44108
9. Comparison of Traditional Small Molecule Drugs and
Biologic Agents
NDA (New Drug Application). ANDA (Abbreviated New Drug Application). BLA (Biologics License Applications).
Source: Special Report: Understanding Key Difference Between Biosimilars and Small Molecule Generics, McMahon Publishing, May 2013.
FEATURES SMALL MOLECULE DRUGS BIOLOGIC AGENTS
EXAMPLE Aspirin (180 Da) Avastin (Monoclonal antibody) (~150,000 Da)
ENTITY Chemical Protein
STRUCTURE Small, simple, well characterized Large, complex, heterogeneous
STABILITY Stable Unstable
MODE OF ADMINISTRATION Usually amenable to ingestion Usually requires injection or infusion
MANUFACTURING PROCESS
Predictable and precise method;
identical copies in batches
Living cell-based complex technology; batch-
to-batch variation, sensitive to storage and
handling
IMMUNOGENICITY Mostly non-immunogenic Immunogenic
APPROVAL PROCESS NDA (Generics = ANDA) BLA (Follow on biologics = BPCIA)
Unlike small molecule generic drugs, biologics cannot be exactly replicated.
44108
10. “Small molecule” Drugs vs Biologics
(Bicycle vs F-16 Fighter Jet Analogy)
• Biological products are generally produced using a living system or
organism
• Biological products may be manufactured through biotechnology,
derived from natural sources, or produced synthetically
11. What is a biosimilar product?
• A biosimilar is a biological product that is highly similar to and has no
clinically meaningful differences from an existing FDA-approved
biologic reference product.
• Small molecule drugs (like oral blood pressure pills) have generics
• Biologics (like Avastin) have biosimilars
• Biosimilars are NOT generics and thus are not directly substitutable
at the pharmacy (more details to come on this topic……)
13. Biosimilar and Innovator Development
Source: www.biosimilarsresourcecenter.org. How Does a Manufacturer Demonstrate Biosimilarity? https://www.biosimilarsresourcecenter.org/faq/how-does-a-manufacturer-demonstrate-biosimilarity/, accessed October
11, 2017. Biosimilarity at each step provides totality of evidence and scientific justification for extrapolation.
INNOVATOR BIOLOGIC APPLICATION BIOSIMILAR APPLICATION
ADDITIONAL CLINICAL
STUDIES
CLINICAL
PHARMACOLOGY
NON-CLINICAL
ANALYTICAL
CLINICAL STUDIES
CLINICAL
PHARMACOLOGY
NON-CLINICAL
ANALYTICAL
EXTENSIVE CLINICAL PROGRAM TARGETED CLINICAL PROGRAM
351(k) application – demonstrate
biosimilarity to its innovator product
351(a) application – demonstrate safety,
purity and potency
44108
14. What is an interchangeable product?
• An interchangeable product is a biosimilar product that meets
additional requirements outlined by the Biologics Price Competition
and Innovation Act. As part of fulfilling these additional
requirements, information is needed to show that an
interchangeable product is expected to produce the same clinical
result as the reference product in any given patient. Also, for
products administered to a patient more than once, the risk in terms
of safety and reduced efficacy of switching back and forth between
an interchangeable product and a reference product will have been
evaluated.
• An interchangeable product may be substituted for the reference
product without the involvement of the prescriber. FDA’s high
standards for approval should assure health care providers that they
can be confident in the safety and effectiveness of an
interchangeable product, just as they would be for an FDA-approved
reference product.
15. INTERCHANGEABLE BIOLOGICAL
PRODUCT
• Biosimilar to the
FDA-approved reference product
• Meets additional standards
for interchangeability
• May be substituted for
the reference product
by a pharmacist without
intervention by prescribing
provider
BIOSIMILAR PRODUCT
BPCIA, Part of the Affordable Care Act, Created
an Abbreviated Licensure Pathway for Biosimilars
Biosimilarity does not imply interchangeability
BPCI Act (Biologics Price Competition and Innovation Act of 2009).
Source: http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/default.htm, accessed November 16,
2017.
• Biological product
• Highly similar to the
FDA-approved biological
“reference” product
• No clinically meaningful
differences in safety and
effectiveness
• Only minor differences in
clinically inactive components
allowable
44108
16. Are biosimilars the same as generic drugs?
• Biosimilars and generic drugs are versions of brand name drugs and may
offer more affordable treatment options to patients. Biosimilars and generics
are each approved through different abbreviated pathways that avoid
duplicating costly clinical trials. But biosimilars are not generics, and there
are important differences between biosimilars and generic drugs.
• For example, the active ingredients of generic drugs are the same as those of
brand name drugs. In addition, the manufacturer of a generic drug must
demonstrate that the generic is bioequivalent to the brand name drug.
• By contrast, biosimilar manufacturers must demonstrate that the biosimilar
is highly similar to the reference product, except for minor differences in
clinically inactive components. Biosimilar manufacturers must also
demonstrate that there are no clinically meaningful differences between the
biosimilar and the reference product in terms of safety and effectiveness.
17. Adalimumab-atto
Biosimilars FDA Naming Convention
Etanercept-szzs
Core name FDA-designated suffix
No recognizable meaning
4 letters
Lowercase
Filgrastim-sndz
Infliximab-abda
Bevacizumb-awwb
Infliximab-dyyb
Adalimumab-adbm
FDA. Nonproprietary naming of biological products: guidance for industry. 2017.
19. Impact of Biosimilars to the Marketplace
• Creates more competition
• More competition should lead to lower drug prices
• To date we have seen a varying range of pricing discounts for biosimilar drugs
• Health plans are continuing to explore how to maximize the value of
biosimilars to make these expensive therapies more affordable
• Example: Insurance may block brand reference product and only cover the biosimilar
• Adoption in the U.S. has been fairly low to date
• Largely due to physician and patient uncertainty about biosimilars, thus often
electing to use the reference brand product
• In comparison, much of Europe has strongly adopted biosimilars use
20. FDA Information on Biosimilars
• https://www.fda.gov/drugs/developmentapprovalprocess/howdrugs
aredevelopedandapproved/approvalapplications/therapeuticbiologic
applications/biosimilars/
22. Reading a manufacturer’s prescribing
information document (aka package insert)
• Suggest reviewing initial section often titled “Highlights of Prescribing
Information” which provides a concise, one-half page summary of
information in the Full Prescribing Information
• Provides quick summary of most important information including:
• Black box warnings
• Indications and usage
• Dosing and administration
• Available dosage forms
• Contraindications
• Warnings and precautions
• Adverse reactions
• Use in special populations (e.g, pregnancy, kidney or liver issues)
• For specific areas of interest, go to that specific section of the
package insert for more detailed information
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38. FDA Prescribing Information Website
• https://dailymed.nlm.nih.gov
• Electronic, user-friendly format
• All FDA approved drugs available for review on this website
• Includes images of drug packaging
42. What to do if you have questions about your medication?
• If an emergency situation, always contact your doctor or call 911 first
• If non-emergency, such as wondering if mild persistent nausea or
diarrhea is caused by your drug therapy, call your pharmacy and ask
to speak directly to the pharmacist
• If you are taking a medication that is mailed to you from a specialty
pharmacy, contact the specialty pharmacy versus your local retail pharmacy
as they likely will be more knowledgeable in that area (most notably cancer)
• Common questions that the specialty pharmacist commonly receives:
• “Is this a side effect of my drug that I am experiencing?”
• “If so, what can I do to address?”
• “Is there available financial support?”
• They can help find manufacturer copay assistance and/or foundation support
• “I’m not feeling any better/different, is my medication working?“
• Important to remain adherent, may be that drug is keeping condition in check and not getting
worse which is a successful outcome. Make sure you are getting routine lab checks (like blood
tests) and MD visits (physical exams) to monitor true response to therapy
43. Q
&
A
SNAP A #STRONGARMSELFIE
Bayer HealthCare will donate $1 for every photo
posted (up to $25,000).
Flex a “strong arm” & post it to Twitter or
Instagram using the hashtag #StrongArmSelfie
Biopharmaceuticals are made by harvesting proteins that are produced and secreted by specially genetically engineered living cells (proteins). The production process is far more complex. The quality of the end product (including therapeutic efficacy and safety) may depend on the manufacturing process.
What are biologic medicines?
A biologic medicine is a large molecule typically derived from living cells and used in the treatment, diagnosis or prevention of disease. Biologic medicines include therapeutic proteins, DNA vaccines, monoclonal antibodies and fusion proteins. Biologic medicines are often 200 to 1,000 times the size of a small molecule drug and are far more complex structurally. They are also highly sensitive to their manufacturing
and handling conditions, making them more difficult to characterize and produce than small molecule drugs. Due to both their size and sensitivity, biologic medicines are almost always injected into a patient’s body and individual patient responses can depend on how a biologic is made.
http://www.amgen.com/pdfs/misc/Biologics_and_Biosimilars_Overview.pdf
Today’s biologic medicines have made a significant difference to the lives of patients with serious illnesses, including cancer, blood conditions, auto-immune disorders such as rheumatoid arthritis (RA) and psoriasis, and neurological disorders like multiple sclerosis. Recreating human proteins into biologic medicines has revolutionized how we treat disease.
Examples of non specialty biologics: FluMist® and Gardasil®
Aspirin versus Humira
The inherently complex nature of biologics makes them expensive to develop and impossible to copy in the manner traditionally associated with the approval of generic drugs. Most biologics are produced in living organisms, such as plant or animal cells, whereas small molecule drugs (most pharmaceuticals) are typically manufactured through chemical synthesis. Thus, even creating "similar" biologics is an inherently unpredictable process.
Highlighting these differences is key to showing why we cannot use the traditional generic approval and interchange process created by the Hatch-Waxman act.
Key Message to convey-
Each pathway has different objective, thus they’re constructed differently-
Reference biologic application- must demonstrate the new drug/biologic is safe and effective based primarily on clinical trials.
Biosimilar application- must demonstrate high similarity between the proposed biosimilar and a reference product, so that it can rely on comparative data of the reference drug. The goal is not to independently establish safety and effectiveness of the proposed biosimilar.
Analytical studies- where Physicochemical characterization occurs; the foundation for showing biosimilarity. The more comprehensive/robust the data, the stronger the justification for selective and targeted approach to animal and human testing.
Examples of analytical studies- Primary amino acid sequence, molecule structure, post translational modifications, lot to lot variability
Non-Clinical studies- where biological characterization occurs using functional assays to exactly understand the drug’s mechanism of action in order to predict the clinical relevance of any observed difference in structure.
Examples of function assays- bioassays, binding assays, enzyme kinetics
Clinical Pharmacology studies- Animal Pharmacokinetic and pharmacodynamic studies and toxicity and immunogencity studies conducted depending on results from previous two steps. Useful if safety uncertainties remain before first-in-man studies.
Clinical studies- Scope and magnitude for clinical studies depends on extent of residual uncertainly from previous steps. No need to independently establish safety and efficacy. Human PK/PD and immunogenicity studies required and are sufficient to demonstrate safety, purity, potency in one or more appropriate conditions of use for which the reference product is licensed.
The FDA will make its determination regarding the approval on the basis of the ‘totality of the evidence’ (evidence provided from steps listed here) and each application will be evaluated on a case by case basis.
Manufacturing sites and any manufacturing changes are closely reviewed by the FDA for clinical relevance
Batch-to-batch variability occurs for reference products, and variability for biosimilars is maintained within this accepted range.
ny change in manufacturing process applicant must notify the FDA of a change to an approved application and before distributing a drug product made with such changes
Objective: regulatory environment/education slides for biosimilars
The Patient Protection and Affordable Care Act (Affordable Care Act), signed into law by President Obama on March 23, 2010, amends the Public Health Service Act (PHS Act) to create an abbreviated licensure pathway for biological products that are demonstrated to be “biosimilar” to or “interchangeable” with an FDA-licensed biological product. This pathway is provided in the part of the law known as the Biologics Price Competition and Innovation Act (BPCI Act). Under the BPCI Act, a biological product may be demonstrated to be “biosimilar” if data show that, among other things, the product is “highly similar” to an already-approved biological product.
A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product. Only minor differences in clinically inactive components are allowable in biosimilar products.
An interchangeable biological product is biosimilar to an FDA-approved reference product and meets additional standards for interchangeability. An interchangeable biological product may be substituted for the reference product by a pharmacist without the intervention of the health care provider who prescribed the reference product.
Biosimilarity does not imply interchangeability
FDA requires licensed biosimilar and interchangeable biological products to meet the Agency’s rigorous standards of safety and efficacy. That means patients and health care professionals will be able to rely upon the safety and effectiveness of the biosimilar or interchangeable product, just as they would the reference product.
Additional info:
What are biosimilars? http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm436399.htm
Biosimilars are often referred to as follow-on biologics, generic biologics or follow-on proteins
Biosimilars are new versions of existing trade-name biological products whose patents have expired
While “highly similar” biosimilars are not “identical” to the reference product
They do not utilize the same living cell line, production process, or raw material as the innovator drug
Biosimilars are not generics.